Aditxt Inc. Common Stock (ADTX)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with business quality and whether there is a durable moat. Aditxt is a 26-employee biotech developing immune-profile products and ADI-100, but the filed numbers show a company far from commercial traction. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $12,159 and net loss was $15.9 million; a year earlier in fiscal Q1 2025, revenue was $1,018 and net loss was $5.7 million. The reported revenue growth of 1,094.40% is real but comes off a tiny base, while profit growth of -179.28% tells the opposite story. Full-year figures are just as stark: FY2025 revenue was $3,195, FY2024 revenue was $133,985, and FY2023 revenue was $645,176, with net losses of $43.1 million, $40.4 million, and $32.7 million. There is no profit in any of the last four years, so FairStock assigns no Peter Lynch category. Financial health is poor. Trailing free cash flow is -$18.6 million, and against a $255,241 market cap at the 2026-10-13 close, the FairStock FCF yield is -7,278.5%; cash burn dwarfs the equity value. The FairStock Piotroski score is 0/9, Altman Z-score is -23.80, and its overall FairStock score is 46/100. ROE is -699.13%, ROCE -50.76%, and diluted EPS -$1,380.80; FairStock also lists P/E and P/B of 0.00. A beta of 0.75 and D/E of 0.76 are the few neutral facts. With P/E and P/B shown as 0.00 and no positive cash flow, valuation cannot be supported by a Graham-style margin of safety. The equity looks like a call option on clinical/regulatory progress, not a business with a moat or predictable compounding. I would watch revenue quality, cash burn, financing dilution, and pipeline milestones.

In plain English: Aditxt is a small healthcare company working on immune-system tests and early-stage treatments. The business looks very weak: it brings in tiny revenue compared with its large losses, and it has not made a profit in the last four years. At its recent market value, the price looks speculative and expensive versus the current numbers because there are no earnings to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer